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Pseudomonas aeruginosa is a common and important pathogen in people with cystic fibrosis (CF). Recently epidemic strains of P. aeruginosa
associated with increased morbidity, have been identified. The method of transmission is not clear, but there is evidence of a potential airborne
route. The aim of this study was to determine whether different strains of P. aeruginosa isolated from people with CF were able to survive within
artificially generated aerosols in an aerobiological chamber.
Viable P. aeruginosa could still be detected up to 45 min after halting generation of the aerosols. All of the strains of P. aeruginosa expressing
a non-mucoid phenotype isolated from people with CF had a reduced ability to survive within aerosols compared to an environmental strain.
Expression of a mucoid phenotype by the strains of P. aeruginosa isolated from people with CF promoted survival in the aerosol model compared
to strains expressing a non-mucoid phenotype.
© 2009 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Pseudomonas aeruginosa; Aerosol1. Introduction
Pseudomonas aeruginosa is the most common and clinically
important pathogen affecting people with cystic fibrosis. P.
aeruginosa is a gram-negative, non-fermentative, aerobic
bacillus belonging to the family Pseudomonadaceae. The
organism is ubiquitous within the environment and is
particularly isolated from moist areas such as the soil and
water. While acquisition of chronic P. aeruginosa infection in
people with CF can occur at any age, many studies suggest that
70–80% of patients are infected during the teenage years [1],
with a number of studies associating chronic infection with
P. aeruginosa with increased mortality [2–4]. Acquisition of
P. aeruginosa infection by people with CF is generally thought
to be from the environment. However, evidence has emerged⁎ Corresponding author. Tel.: +44 113 2065702.
E-mail address: i.j.clifton@btinternet.com (I.J. Clifton).
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doi:10.1016/j.jcf.2009.11.004recently that cross-infection of certain strains of P aeruginosa
can occur between people with CF [5–8]. Infection with some
of these strains is associated with increased morbidity and
treatment burden compared to infection with non-epidemic
strains [9,10]. The method of transmission between patients is
not clear, however there is some evidence that the airborne route
may play an important contributory role [11,12]. In a previous
study involving a laminar airflow model, it was found that while
little difference existed between strains of P. aeruginosa
expressing a non-mucoid phenotype, P. aeruginosa strains
expressing a mucoid phenotype appeared to have a survival
advantage in artificially generated aerosols [13]. However, the
laminar flow model was limited in its ability to study the long-
term survival of droplet nuclei in air, and therefore the present
study was devised to characterise differences in aerosol survival
for a number of strains of P. aeruginosa expressing mucoid and
non-mucoid phenotypes using a decay model in an aerobiolog-
ical chamber.d by Elsevier B.V. All rights reserved.
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2.1. Bacterial strains
Isolates of 3 of the strains, Unique CF, Leeds Paediatric and
Liverpool, were obtained expressing both mucoid and non-
mucoid phenotypes. The remaining strains were only expressed
a non-mucoid phenotype (see Table 1). P. aeruginosa (NCIMB
10848) was obtained from the National Collection of Industrial
and Marine Bacteria. Clinical isolates of P. aeruginosa were
obtained from Department of Microbiology, Leeds General
Infirmary and Centre for Infectious Diseases, University of
Edinburgh.
2.2. Preparation of bacteria for nebulisation
The bacteria were grown to their maximum stationary phase
cell concentration in nutrient broth then stored in stored in 40%
(v v−1) glycerol solution at −20 °C until required. The frozen
cultures were defrosted and placed in the nebuliser solution 1 h
prior to the start of nebulisation.
2.3. Aerosol decay model
The decay experiments were undertaken in a Class II
aerobiological chamber, which had a volume of 32 m3. During
experimentation the air temperature, relative humidity and ven-
tilation air change rate were maintained at 21 °C±1 °C, 50%±5%
RHand 6 AC h−1 respectively. The environmental conditionswere
chosen to approximate conditions found within a hospital
environment [14]. Aerosols were delivered into the centre of
the chamber by a Collison 3-jet nebuliser [15] (BGI, USA)
operating at 6 Lmin−1 and 103.4 kPa, containing 106 CFU mL−1
of P. aeruginosa suspended in 100 mL of 1/4×Ringers solution
for 1 h. Aerosol generation was then stopped and standard air
samples were taken at 0 min, 3 min, 6 min, 9 min, 12 min, 15 min,
25 min, 35 min and 45 min following stopping of aerosol
generation. Air samples were taken by drawing 56.6 L of air
(28.3 Lmin−1) through an Andersen 6-stage impactor [16]
(Andersen Inc, USA) containing nutrient agar plates. The nutrient
agar plates were then incubated at 37 °C for 24 h, the numbers of
colonies on each plate counted, and the count corrected usingTable 1
Bacterial strains.
Bacterial strain Mucoid phenotype Epidemic strain Identification
Environmental Non-mucoid No NCIMB 10848
Manchester Non-mucoid Yes Jones et al. [5]
Seacroft Non-mucoid Yes 4390416-2
Liverpool/Seacroft Non-mucoid Yes 4390195
Leeds Paediatric Non-mucoid Yes Denton et al. [7]
Mucoid Yes
Liverpool Non-mucoid Yes McCallum et al. [6]
Mucoid Yes
Unique CF Non-mucoid No 4412061
Mucoid No 43903641positive-hole correction tables [17] to account for deposition of
multiple aerosol particles containing cells at the same deposition
site [18]. The concentration of viable bacteria in the air sample was
then calculated. All experiments were undertaken in triplicate.
2.4. Statistical analysis
The experimental data was modeled to a first order decay
model (see Eq. (1)) using GraphPad 5.01 (GraphPad Software
Inc) using least squares error analysis. Comparisons between
curves were made by determining if there was a significant
difference between the inactivation rate k using the F-test. A P
value of b0.05 was deemed significant.
logeðNtÞ = logeðN0Þ−kt
N0 = concentration of bacteria at time 0 ðCFUL1Þ
Nt = concentration of bacteria at time t ðCFUL1Þ
k = inactivation rateðh1Þ
t = timeðhÞ
ðEq: 1—first order decay kineticsÞ
In such a model the inactivation rate k represents the
combined effect of natural biological decay arising from loss of
bacterial viability and the removal of airborne particles from the
aerobiological chamber by the action of the ventilation air [19]
(see Eq. (2)).
k = kbio + kvent
k = inactivation rate ðh1Þ
kbio = inactivation rate due to biological inactivation ðh1Þ
kvent = inactivation rate due to ventilation ðACh1Þ
ðEq: 2—factors affecting the inactivation rate kÞ
In the study the value of k was determined experimentally
and then used to calculate the experimental and biological half-
lives using Eq. (3).
t1=2 =
logeð0:5Þ
k
t1=2 = half lifeðhÞ
k = inactivation rate ðh1Þ
ðEq: 3—calculation of half  life from inactivation rateÞ
Due to the relatively high ventilation rate (i.e. 6 AC h−1)
used in the chamber during the experiments, the mean particle
residence time was only 10 min — much too short for most
aerosol particles to settle out under the influence of gravity.
Consequently, the effect of particle deposition on the chamber
surfaces was assumed to be minimal and thus ignored in the
model.
3. Results
The environmental strain and all three strains of P.
aeruginosa expressing a mucoid phenotype could be isolated
Fig. 1. Decay curves for different strains of P. aeruginosa generated in
aerobiological chamber model.
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(see Fig. 1).
The overall results of the various experiments are presented
in Table 2. From this it can be seen that there is great variability
between the various strains tested, despite the fact that control
samples from the nebuliser suspension demonstrated that
the concentration of all the strains of P. aeruginosa was 106
CFU mL−1 both pre- and post-nebulisation. With the exception of
the environmental strain, the strains of P. aeruginosa expressing a
mucoid phenotype exhibited significantly smaller values for kbio
and therefore correspondingly longer biological half-lives, t1/2bio,
compared with their non-mucoid counterparts (Unique vs Unique
mucoid CF Pb0.0001; Paediatric vs Paediatric mucoid Pb0001;
Liverpool vs Liverpool mucoid Pb0.0001).Table 2
Biological inactivation rates (kbio) and half life (t1/2) for each strain of
P. aeruginosa.
Bacterial
strain
k
(h−1)
kbio
(h−1)
kvent
(AC h−1)
t1/2exp
(min)
t1/2bio
(min)
R2
Environmental 15.3 9.3 6.0 2.727 4.495 0.6485
Liverpool 53.2 47.2 6.0 0.782 0.882 0.8051
Liverpool
mucoid
16.4 10.4 6.0 2.532 3.989 0.8883
Manchester 43.2 37.2 6.0 0.964 1.119 0.9655
Paediatric 38.0 32.0 6.0 1.095 1.300 0.9265
Paediatric
mucoid
16.6 10.6 6.0 2.508 3.931 0.9284
Seacroft 38.6 32.6 6.0 1.078 1.277 0.8718
Seacroft/
Liverpool
59.9 53.9 6.0 0.695 0.772 0.9681
Unique CF 43.6 37.6 6.0 0.954 1.106 0.9221
Unique CF
mucoid
16.2 10.2 6.0 2.569 4.082 0.9588There was no significant difference between the value for k
of the 3 CF strains of P. aeruginosa expressing a mucoid
phenotype and the environmental strain of P. aeruginosa (F-test
P=0.9373). The CF strains of P. aeruginosa expressing a non-
mucoid phenotype formed two groups; one contained the
Manchester, Seacroft, Paediatric and Unique strains (F-test
P=0.9059) and the Liverpool and Liverpool/Seacroft strains
formed the remaining group (F-test P=0.1932). The environ-
mental strain of P. aeruginosa had a significantly smaller value
for k and hence a much longer biological half-life than all of the
CF strains expressing a non-mucoid phenotype (Environmental
vs Non-mucoid CF strains F-test Pb0.0001).
4. Discussion
Two studies undertaken at CF centres in the UK raised
the possibility of airborne dissemination of transmissible P.
aeruginosa from people as a potential route of cross-infection
[11,12]. Using a Cassela slit sampler and a Pseudomonas-
selective agar Panagea et al. isolated the Liverpool epidemic
strain of P. aeruginosa from the air in cubicles and the corridors
of the CF unit up to 3 h after the individuals with CF had left the
area [12]. In this study the only strain of P. aeruginosa isolated
from the air was the Liverpool transmissible strain. Jones et al.
sampled the air following people with CF performing
spirometry measurement, airway clearance and nebulisation
using a SAS air sampler and Pseudomonas-selective agar and
isolated both non-epidemic strains and the Manchester epidemic
strain of P. aeruginosa [11].
A more recent study undertaken in a French CF unit used an
Air Test Omega impactor air sampler combined with a Pseu-
domonas-selective media to sample the air in the CF hospital
ward, spirometry measurement area and the hospital leisure
centre. In this study the levels of airborne contamination within
the bedroom were significantly higher after the person with CF
had woken up or performed physiotherapy, than after the
bedroom had been cleaned. Over half of the 22 people in this
study infected with P. aeruginosa had air samples taken from
their bedroom which were positive for P. aeruginosa. In 6 cases
where P. aeruginosa was isolated from the air, the strain was
genetically identical to the strain isolated from the patient's
sputum. The mean concentration of P. aeruginosa in the air
samples after waking up and following physiotherapy was
154.3 CFU m−3 and 40.7 CFU m−3 respectively [20]. An
Australian study using a cough aerosol sampling system
demonstrated 25 of 26 people with CF chronically infected
with P. aeruginosa were able to produce aerosols containing
viable bacteria. The majority of these bacteria were contained
within aerosol particles b3.3 µm in diameter [21]. Collectively
the above findings suggest that aerosol particles containing
P. aeruginosa may be frequently liberated into the air from
individuals with CF and may represent a potential reservoir
for cross-infection.
Gram-negative bacteria are generally not thought to survive
well in the aerosolised state and this may, in part, explain why
some have dismissed the possibility of P. aeruginosa cross-
infection occurring via the airborne route. However, the results
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P. aeruginosa expressing a mucoid phenotype survive well in
the aerosolised state for many minutes, suggesting that cross-
infection could occur via the airborne route. These findings
support the data presented previously in a laminar flow study,
which found the expression of a mucoid phenotype to be
beneficial to the survival of the bacteria in the aerosolised state
[13]. The strains of P. aeruginosa isolated from people with CF
expressing a non-mucoid phenotype CF strains appear to have a
reduced ability to survive when aerosolised when compared to
the environmental strain of P. aeruginosa which is also non-
mucoid. This may be a reflection that the environmental strain is
more equipped for dealing with environmental insults such as
desiccation, whereas isolates of P. aeruginosa isolated from
people with CF will have evolved to survive within the CF lung
and may have lost the ability to resist environmental insults. The
epidemic strains of P. aeruginosa did not appear to have a
survival advantage within the aerosols when compared to the
non-epidemic strains. This would suggest that improved
environmental survival may not account for the spread of
epidemic strains of P. aeruginosa between people with CF.
Other factors such as evasion of host defences or improved
binding to respiratory epithelial cells may be important for
cross-infection of certain strains of P. aeruginosa.
From the results presented in Table 2 it is evident that the
value of kbio CF strains expressing a mucoid phenotype is an
order of magnitude lower than that for CF strains expressing a
non-mucoid phenotype. This means that in CF treatment rooms
mucoid P. aeruginosa strains have the potential to remain
viable for considerable periods of time if liberated into the air in
respiratory droplet nuclei. This suggests that the intervention of
improved room ventilation might be beneficial in such facilities.
By increasing the ventilation rate it is possible to dilute the
concentration of infectious particles in the room air by flushing
them from the space. With respect to this, the data from the
aerobiological chamber has the potential to provide guidance
regarding infection control measures designed to reduce the
potential risk of cross-infection between people with CF. By
combining Eqs. (1) and (2) it is possible to derive an equation
which incorporates both the biological inactivation rate, kbio,Table 3
Time (min) required to remove 90% of bacteria from a room space for strains of
P. aeruginosa at various ventilation rates (calculated using Eq. (4)).
Bacterial strain Ventilation rate in area (AC h−1)
0 3 6 9 12 15
Environmental 14.9 11.3 9.1 7.6 6.5 5.7
Liverpool 2.9 2.8 2.6 2.5 2.3 2.2
Liverpool mucoid 13.3 10.3 8.4 7.1 6.2 5.4
Manchester 3.7 3.4 3.2 3.0 2.8 2.6
Paediatric 4.3 3.9 3.6 3.4 3.1 2.9
Paediatric mucoid 13.1 10.2 8.3 7.1 6.1 5.4
Seacroft 4.2 3.9 3.6 3.3 3.1 2.9
Seacroft/Liverpool 2.6 2.4 2.3 2.2 2.1 2.0
Unique CF 3.7 3.4 3.2 3.0 2.8 2.6
Unique CF mucoid 13.6 10.5 8.5 7.2 6.2 5.5and the removal rate due to the ventilation air, kvent (see Eq. (4)).
Using this equation it is possible to evaluate the effect that
varying the ventilation rate has on the concentration of viable
bacteria in room air.
logeðNtÞ = logeðN0Þ−ðkbio + kventÞ × t
N0 = concentration of bacteria at time 0 ðCFUL1Þ
Nt = concentration of bacteria at time t ðCFUL1Þ
kbio = inactivation rate due to biological inactivation ðh1Þ
kvent = inactivation rate due to ventilation ðACh1Þ
t = time ðhÞ
ðEq: 4—first order decay taking into account biological decay and ventilationÞ
Using Eq. (4) it is possible to estimate how the concentration
of bioaerosol particles will vary with time for any clinical space.
The results in Table 3 are calculated using Eq. (4). These show
the time required to remove 90% of bacteria from a room space
under various ventilation conditions. These data suggest that,
providing that the ventilation rate is greater than 6 AC h−1,
within 10 min of an individual with CF leaving a clinical area,
over 90% of the P. aeruginosa that may have disseminated into
the air, will have been removed through a combination of
ventilation and biological inactivation. Although, the UK
Department of Health guidelines for hospital ventilation [14]
do not specifically specify ventilation rates (i.e. outdoor air
changes) rooms where treatment of people with CF is
undertaken, they suggest a ventilation rate of 12 AC h−1 for
areas such as infectious diseases isolation rooms, critical care
areas and wards used for the care of neutropaenic patients. If
this ventilation rate was adopted in the context of the care of
people with CF, then allowing 7 min between one person with
CF leaving an area and another person with CF entering the area
should ensure the removal of N90% of the bacteria from the
room air, thus greatly reducing the risk of cross-infection.
There are limitations to this study due to the small numbers
of P. aeruginosa strains studied and we would suggest further
studies with a greater number of strains to try and determine
both genetic and phenotypic factors that may influence the
survival of P. aeruginosa within aerosols.
An important consideration when trying to determine the risk
of contagion is the infectious dose required to establish lung
colonization/infection in people with CF following inhalation of
aerosol particles continuing P. aeruginosa. Unfortunately, no
data exists regarding this issue and it would not be ethical to
undertake studies to try and determine the infectious dose in
people with CF. However, data from research related to
biological warfare agents suggests that bacteria can produce
disease with the inhalation of as few as 1–100 organisms [22].
Given the defects in the innate immunity of the CF lung, it is
therefore entirely plausible that P. aeruginosa cross-infection
could be occurring via the airborne route in the clinical setting.
However, further work needs to be undertaken to quantify the
infectious dose required. A methodology does exist for
evaluating the infectious dose associated with airborne diseases
such as tuberculosis [23,24]. However, this methodology has
never been applied to the care of people with CF, mainly
68 I.J. Clifton et al. / Journal of Cystic Fibrosis 9 (2010) 64–68because of the multiple confounding factors. Consequently,
little information exists with which to assess the performance of
potential interventions such as improved room ventilation,
ultra-violet light, ionization of the air, or even drying of the air.
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